Journal: Neurology and Therapy

Article Title: Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

doi: 10.1007/s40120-023-00541-1

Figure Lengend Snippet: Characteristics of amyloid-targeting and tau-targeting antibodies

Article Snippet: , Ponezumab , 2 , Humanized Ig G2a , M, O, F (Aß40 only) , C-Terminal 30–40 , IV , Part A: 0.1/0.5/1 mg/kg Part B: 3/8.5 mg/kg Q60D , Pfizer.

Techniques: Binding Assay

Journal: Advanced Therapeutics

Article Title: Human Ferritin Platform and Its Optimized Structures to Enhance Anti‐Cancer Immunity

doi: 10.1002/adtp.202000208

Figure Lengend Snippet: Figure 1. Schematic illustration of huHF-platform-derived optimized structures to enhance anti-tumor immunity and their application to adjuvant- and antibody-free cancer immunotherapy. The optimized structures to enhance anti-tumor immunity—multi-copies of tumor-specific antigen (TSA)- and immune checkpoint molecule (ICM)-presenting huHFs—were constructed through structure-guided, molecular design of huHF platform with preservation of huHF-intrinsic affinity for TfR on DCs. The huHF-platform-derived optimized structures were synthesized in Escherichia coli and used as anti-cancer vaccine and IC blocker for cancer immunotherapy: The TSA-presenting huHFs efficiently target TSAs at DCs, activate cross-presentation of TSAs and maturation of DCs, and accordingly elicit TSA-specific CD8+ T cell activation, which enables adjuvant-free cancer vaccination. ICM-huHF disrupts a cognate negative immune regulatory checkpoint and restores CD8+ T cell activities by suppressing Th17 cell immunity, which significantly reduces systemic immune adverse events. (In this study, melanoma gp100 and colon cancer AH1 antigens were used as TSAs, and an active domain of PD1 was used as an ICM.)

Article Snippet: Through the three-time footpad injections with 1-week interval, we immunized the live mice (C57BL/6) with PBS, gp100, huHF, N-, AB-, BC-, CD-, DE-, or C-gp100-huHF (50 nmol kg−1), followed by the subcutaneous inoculation of B16F10 cells (1 × 105 cells) (ATCC CRL-6475) to the immunized C57BL/6 mice (Figure 3h).

Techniques: Derivative Assay, Adjuvant, Construct, Preserving, Synthesized, Activation Assay

Journal: Advanced Therapeutics

Article Title: Human Ferritin Platform and Its Optimized Structures to Enhance Anti‐Cancer Immunity

doi: 10.1002/adtp.202000208

Figure Lengend Snippet: Figure 2. Structure-guided design, biosynthesis, and characterization of TSA (gp100)- and PD1-presenting huHFs. a) 3D structures of differently de- signed gp100-huHFs (i.e., N-, AB-, BC-, CD-, DE-, and C-gp100-huHF) from molecular modeling (homology model and MD) and transmission electron microscopy (TEM) and dynamic light scattering (DLS) analysis results of the synthesized and purified gp100-huHFs. b) Dissociation constants (Kd) measured in the binding of each gp100-huHF to recombinant TfR (standard). c) Fluorescence intensities measured for the DC cultures treated with

Article Snippet: Through the three-time footpad injections with 1-week interval, we immunized the live mice (C57BL/6) with PBS, gp100, huHF, N-, AB-, BC-, CD-, DE-, or C-gp100-huHF (50 nmol kg−1), followed by the subcutaneous inoculation of B16F10 cells (1 × 105 cells) (ATCC CRL-6475) to the immunized C57BL/6 mice (Figure 3h).

Techniques: Transmission Assay, Electron Microscopy, Synthesized, Binding Assay, Recombinant, Fluorescence

Journal: Advanced Therapeutics

Article Title: Human Ferritin Platform and Its Optimized Structures to Enhance Anti‐Cancer Immunity

doi: 10.1002/adtp.202000208

Figure Lengend Snippet: Figure 3. In vitro DC activation and maturation by and in vivo anti-tumor performance of antigen-presenting huHF (CD-OVA/gp100-huHF) as a cancer vaccine. a) Quantification of MHC-I-mediated cross-presentation of antigen (OVA: ovalbumin257-264 peptide) through FACS analysis of DCs stained with PE-labeled anti-MHC-I-OVA complex monoclonal IgG (25-D1.16), at 24 h after DCs were treated with OVA-huHFs, huHF, and PBS. b) Time-course quantification of MHC-I-mediated cross-presentation of OVA antigen in Figure 3a. c) Quantification of MHC-I-mediated cross-presentation of OVA

Article Snippet: Through the three-time footpad injections with 1-week interval, we immunized the live mice (C57BL/6) with PBS, gp100, huHF, N-, AB-, BC-, CD-, DE-, or C-gp100-huHF (50 nmol kg−1), followed by the subcutaneous inoculation of B16F10 cells (1 × 105 cells) (ATCC CRL-6475) to the immunized C57BL/6 mice (Figure 3h).

Techniques: In Vitro, Activation Assay, In Vivo, Staining, Labeling

Journal: Advanced Therapeutics

Article Title: Human Ferritin Platform and Its Optimized Structures to Enhance Anti‐Cancer Immunity

doi: 10.1002/adtp.202000208

Figure Lengend Snippet: Figure 5. In vivo anti-tumor and Th17-suppressing performance of combination immunotherapy using both CD-gp100/AH1-huHF and PD1-huHF. a) Time schedule of combination immunotherapy through the injection (six times with 3-day interval) of 1) PD1-huHF (25 nmol kg−1) + CD-AH1/

Article Snippet: Through the three-time footpad injections with 1-week interval, we immunized the live mice (C57BL/6) with PBS, gp100, huHF, N-, AB-, BC-, CD-, DE-, or C-gp100-huHF (50 nmol kg−1), followed by the subcutaneous inoculation of B16F10 cells (1 × 105 cells) (ATCC CRL-6475) to the immunized C57BL/6 mice (Figure 3h).

Techniques: In Vivo, Injection

Journal: Advanced Therapeutics

Article Title: Human Ferritin Platform and Its Optimized Structures to Enhance Anti‐Cancer Immunity

doi: 10.1002/adtp.202000208

Figure Lengend Snippet: Figure 6. Long-term anti-tumor immunity generated by combination immunotherapy. a) Time schedule of combination immunotherapy through the injection (six times with 3-day interval) of PD1-huHF/ɑ-PD-L1 (25 nmol kg−1) + CD-AH1-huHF (10 nmol kg−1) to CT26 (AH1+)-bearing BALB/c mice (n = 5), which was immediately followed by CT26 excision surgery and subsequent rechallenge of CT26 through IV and subcutaneous injection. (PBS were also injected as control.) Time-course change of subcutaneous tumor (CT26) volume (b) and overall survival rate (c) in each group of tumor-rechallenged mice (a). d) Detection of TSA (AH1, gp100)-specific CD8+ T cells through FACS analysis of the blood samples from each group of CT26-rechallenged mice (a–c). e) Metastatic tumor nodules of lung (CT26) that is derived from intravenously rechallenged tumor in each group of BALB/c mice (a–c). Error bars, mean ± SD; **, p < 0.005; ***, p < 0.001.

Article Snippet: Through the three-time footpad injections with 1-week interval, we immunized the live mice (C57BL/6) with PBS, gp100, huHF, N-, AB-, BC-, CD-, DE-, or C-gp100-huHF (50 nmol kg−1), followed by the subcutaneous inoculation of B16F10 cells (1 × 105 cells) (ATCC CRL-6475) to the immunized C57BL/6 mice (Figure 3h).

Techniques: Generated, Injection, Control, Derivative Assay